Soft Tissue Sarcoma (STS) Clinical Trial
Soft Tissue Sarcoma (STS) is a rare tumor but can grow in different areas, for example, in
60% in limbs and about 20 % in retroperitoneum; and frequently is inoperable. Despite novel
therapy in advanced cases survival is still short, approximately 12 month.
Pazopanib oral angiogenesis inhibitor was recently shown as promising drug for advanced
pretreated STS.
Functional imaging especially F18-FDG PET/CT is a good modality for FDG avid tumor either
for pre- / post- treatment evaluation or follow up.
Early detection of treatment response to therapy by whole body FDG PET/CT allows for change
of treatment as early as possible,when the tumor is non-responsive before serious side
effects appear or before depletion of body resources.
The aim of the study is to investigate the contribution of FDG PET/CT to assessment of
treatment response.
| Status | Not yet recruiting |
| Enrollment | 30 |
| Est. completion date | May 2013 |
| Est. primary completion date | November 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients with advanced Soft Tissue Sarcoma prior to pazopanib treatment Exclusion Criteria: - Other treatment - FDG negative tumor |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Israel | Hadassah Hebrew University Medical Center | Jerusalem |
| Lead Sponsor | Collaborator |
|---|---|
| Hadassah Medical Organization |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Measure of extent and intensity (standardized uptake value - SUV) of disease demonstrated on PET/CT images before and after treatment. | 1 week | ||
| Primary | determination of treatment efficiency by comparison of PET data (SUV) with CT changes (cm)in 3 studies and clinical information. | 4 week | ||
| Secondary | prediction of treatment efficiency | 6 weeks |